Other Issues

CHPA continues to closely monitor the rapidly-evolving Coronavirus Disease 2019 (COVID-19) outbreak.

The four leading trade associations representing the dietary supplement industry are concerned that some marketers of dietary supplements may be promoting them with claims of prevention or treatment of Coronavirus.

Medical and patient groups, public health experts, FDA, and others join the Consumer Healthcare Products Association in opposing the addition of acetaminophen to the Proposition 65 list.

Acetaminophen was chosen for review by OEHHA in part because the Prop 65 regulation emphasizes chemicals with “widespread exposure.” The Carcinogen Identification Committee will review the information on acetaminophen and cancer to determine whether acetaminophen should be listed as a carcinogen under Proposition 65.

The observational Internet survey results pre-published in the American Journal of Gastroenterology reporting an association between use of proton-pump inhibitor (PPI) medicines and self-reported positive tests for COVID-19 among people taking PPIs do not prove cause-and-effect.

The 2019 results from the NIDA and University of Michigan’s annual drug abuse survey, Monitoring the Future, show that the number of teens using OTC cough medicine containing DXM to get high decreased slightly.

CHPA today applauds the U.S. Food and Drug Administration for enforcing existing provisions in the Federal Food, Drug, and Cosmetic Act by sending warning letters to 15 companies illegally marketing cannabidiol products.